Biological interactions are at the core of health and disease. We build AI models that explain how molecules interact across scales, from atomic interfaces to biological networks. Our mission is to make early-stage drug discovery outcomes mechanistically predictable.
Location: Switzerland
Total raised: $375.87K
Investors 1
| Date | Name | Website |
| 27.12.2024 | Venture Ki... | venturekic... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.09.2025 | Pre-Seed | $187.94K | Venture Ki... |
| 15.09.2025 | Grant | $187.94K | Venture Ki... |
Mentions in press and media 3
| Date | Title | Description |
| 15.09.2025 | Lemna Bio has received CHF 150,000 from Venture Kick to redefine drug discovery | Drug discovery today faces decade-long timelines, soaring costs, and a 90% clinical failure rate — with up to 50% of failures caused by flawed biological assumptions, such as selecting the wrong target. Current tools struggle to capture bio... |
| 15.09.2025 | Lemna Bio receives CHF 150k from Venture Kick to redefine drug discovery with AI | Drug discovery today faces decade-long timelines, soaring costs, and a 90% clinical failure rate — with up to 50% of failures caused by flawed biological assumptions, such as selecting the wrong target. Current tools struggle to capture bi... |
| 22.08.2025 | DayOne Accelerator reveals latest cohort | The DayOne Accelerator is a three-month hybrid program for high-potential, early-stage techbio and healthtech ventures working at the intersection with Pharma R&D. Following the program revamp this year, the program coordinators are no... |